Comparison of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay results in patients with neuroendocrine tumours

被引：0
|
作者：
Rodrigues, M. [1 ]
Heute, D. [1 ]
Gabriel, M. [1 ]
Putzer, D. [1 ]
Griesmacher, A. [1 ]
Virgolini, I. [1 ]
机构：
[1] Hietzing Hosp, Inst Nucl Med, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S175 / S175
页数：1
相关论文
共 50 条
  • [41] The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA- DPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
    Stolz, Barbara
    Weckbecker, Gisbert
    Smith-Jones, Peter M.
    Albert, Rainer
    Raulf, Friedrich
    Bruns, Christian
    European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25 (07): : 668 - 674
  • [42] Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors
    Stokkel, Marcel P. M.
    Rietbergen, Daphne D.
    Korse, Catharina M.
    Taal, Babs G.
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (08) : 731 - 737
  • [43] Biodistribution and dosimetry of indium-111 labeled DOTA-tyr3-octreotide (DOTATOC) patients with neuroendocrine tumors.
    Chinol, M
    Macke, HR
    Cremonesi, M
    Ferrari, M
    Jermann, E
    Fiorenza, M
    Paganelli, G
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 221P - 221P
  • [44] Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide:: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
    De Jong, M
    Bernard, BF
    De Bruin, E
    Van Gameren, A
    Bakker, WH
    Visser, TJ
    Macke, HR
    Krenning, EP
    NUCLEAR MEDICINE COMMUNICATIONS, 1998, 19 (03) : 283 - 288
  • [45] SOMATOSTATIN RECEPTOR SCINTIGRAPHY WITH [IN-111-DTPA-D-PHE(1)]- AND [I-123-TYR(3)]-OCTREOTIDE - THE ROTTERDAM EXPERIENCE WITH MORE THAN 1000 PATIENTS
    KRENNING, EP
    KWEKKEBOOM, DJ
    BAKKER, WH
    BREEMAN, WAP
    KOOIJ, PPM
    OEI, HY
    VANHAGEN, M
    POSTEMA, PTE
    DEJONG, M
    REUBI, JC
    VISSER, TJ
    REIJS, AEM
    HOFLAND, LJ
    KOPER, JW
    LAMBERTS, SWJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1993, 20 (08): : 716 - 731
  • [46] Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group
    Chinol, M
    Bodei, L
    Cremonesi, M
    Paganelli, G
    SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) : 141 - 147
  • [47] Receptor PET/CT Imaging of Neuroendocrine Tumours Using the Ga-68 Labelled, High Affinity Somatostatin Analogue DOTA-1-Nal3-octreotide (DOTA-NOC): Clinical Results in 327 Patients
    Baum, R. P.
    Niesen, A.
    Leonhardi, J.
    Wortmann, R.
    Mueller, D.
    Roesch, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S54 - S55
  • [48] Comparative study of In-111-DOTA-Lanreotide (LAN), In-111-DTPA-D-Phe-1-Octreotide (OCT), In-111-DOTA-Tyr-3-Octreotide (TOCT) and F-18-FDG-PET in neuroendocrine tumor patients
    Virgolini, I
    Kurtaran, A
    Smith-Jones, P
    Havlik, E
    Traub, T
    Leimer, M
    Ofluoglu, S
    Andreae, F
    Raderer, M
    Angelberger, P
    Becherer, A
    Niederle, B
    Kletter, K
    Schima, W
    Dudczak, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1156 - 1156
  • [49] Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
    Lisa Bodei
    Marta Cremonesi
    Chiara Grana
    Paola Rocca
    Mirco Bartolomei
    Marco Chinol
    Giovanni Paganelli
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 1038 - 1046
  • [50] Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
    Bodei, L
    Cremonesi, M
    Grana, C
    Rocca, P
    Bartolomei, M
    Chinol, M
    Paganelli, G
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (07) : 1038 - 1046
12345